Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 51, Issue 1, Pages 289-297Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2017.4016
Keywords
miR-122; clear cell renal cell carcinoma; occludin
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [25670025]
- Project MEET, Osaka University Graduate School of Medicine
- Takeda Pharmaceutical
- Novartis Pharma
- Astra Zeneca
- Grants-in-Aid for Scientific Research [25670025] Funding Source: KAKEN
Ask authors/readers for more resources
Renal cell carcinoma (RCC) is the most common neoplasm of the adult kidney, and clear cell RCC (ccRCC) represents its most common histological subtype. Although several studies have reported high expression of miR-122 in ccRCC, its physiological role remains unclear. To clarify the role of miR-122 in ccRCC, we compared miR-122 expression levels in non-cancerous tissue and ccRCC. Significant upregulation of miR-122 was observed in ccRCC specimens. Moreover, ccRCC patients with high miR-122 expression showed poor progression-free survival compared to those with low miR-122 expression. Overexpression of miR-122 using an miRNA mimic promoted proliferation, migration, and invasion activities of ccRCC cells. miR-122 directly targets occludin, a known component of tight junctions. Occludin knockdown promoted the cell migration activity but not proliferation or invasion activities of ccRCC cells. In human clinical specimens, miR-122 expression inversely correlated with occludin protein expression. These findings show that miR-122 is an oncomiR in ccRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available